Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.44 |
| ▸ | WNT3A | P56704 | 3/20 | 0.44 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16182225 | 0.83 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL960151 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL960630 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL730574 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL702375 | 0.79 | PRMT5 (0.61) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL2227955 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL3061437 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL254885 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL29562338 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL18901282 | 0.79 | KDM4E (0.47) | KDM4EGAAPDPK1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-01-10 | — | — | US | claimed |
| EP-3398950-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-11-07 | — | — | EP | claimed |
| CN-117120419-A | KLK5 bicyclic heteroaromatic inhibitors | 拜奥克里斯特制药公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-3398950-B1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | PRECEDO PHARMACEUTICALS CO LTD (CN) | 2021-08-11 | — | — | EP | disclosed |
| CN-106928231-B | Novel EGFR wild type and mutant kinase inhibitors | 合肥中科普瑞昇生物医药科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | PRECEDO PHARMACEUTICALS CO., LTD. (CN) | 2020-09-22 | — | — | US | disclosed |
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-01-10 | — | — | US | disclosed |
| EP-3398950-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | EGFR, ERBB2, ERBB3 | KDM4E 4090/4885GAA 2171/4885PDPK1 330/4885 |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | KDM4E 2196/4885GAA 4544/4885PDPK1 2226/4885 |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | KDM4E 3664/4885GAA 3935/4885PDPK1 2113/4885 |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | KDM4E 3664/4885GAA 3935/4885PDPK1 2113/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | KDM4E 2989/4885GAA 4227/4885PDPK1 2860/4885 |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | EGFR, ERBB2, ERBB3 | KDM4E 4059/4885GAA 1664/4885PDPK1 347/4885 |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | KDM4E 2641/4885GAA 4168/4885PDPK1 2225/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | KDM4E 2811/4885GAA 3745/4885PDPK1 2039/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | KDM4E 2927/4885GAA 4233/4885PDPK1 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.